Update on the pathogenic potential and treatment options for Blastocystis sp
نویسندگان
چکیده
منابع مشابه
Update on the pathogenic potential and treatment options for Blastocystis sp
Although Blastocystis is one of the most common enteric parasites, there is still much controversy surrounding the pathogenicity and potential treatment options for this parasite. In this review we look at the evidence supporting Blastocystis as an intestinal pathogen as shown by numerous case studies and several in vivo studies and the evidence against. We describe the chronic nature of some i...
متن کاملLocation and Pathogenic Potential of Blastocystis in the Porcine Intestine
Blastocystis is an ubiquitous, enteric protozoan of humans and many other species. Human infection has been associated with gastrointestinal disease such as irritable bowel syndrome, however, this remains unproven. A relevant animal model is needed to investigate the pathogenesis/pathogenicity of Blastocystis. We concluded previously that pigs are likely natural hosts of Blastocystis with a pot...
متن کاملPneumonia: Update on Causes--and Treatment Options
Pneumonia is one of the most common conditions encountered by primary care providers. Certain organisms cause pneumonia in particular age groups. For example, group B streptococci, Gram-negative bacilli Escherichia coli in particular) and, rarely, Listeria monocytogenes cause pneumonia in neonates. In infants younger than 3 months, group B streptococci and organisms encountered by older childre...
متن کاملUpdate on the treatment options for multiple sclerosis.
Recent progress in the treatment of multiple sclerosis (MS) is remarkable, and the introduction of new therapies is yielding improvements in the management of MS. Furthermore, clinical trials with many different types of agents, especially selected monoclonal antibodies, have been undertaken or are ongoing, and some of the agents involved will probably be available as treatments for MS in the n...
متن کاملTreatment options for obesity and potential therapies on the horizon.
Orlistat (Xenical, Alli) Orlistat (Xenical, Roche) is one of only two medications approved by the FDA for the treatment of obesity. A lipase inhibitor, it prevents the breakdown of dietary triglycerides to fatty acids and monoglycerides. The prescribed dose of 120 mg three times daily is taken with meals and prevents approximately 30% of ingested fat from being absorbed.6 According to a meta-an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gut Pathogens
سال: 2014
ISSN: 1757-4749
DOI: 10.1186/1757-4749-6-17